Solid tumors account for the majority of cancer cases worldwide and remain one of the greatest challenges in modern medicine. While significant advances have been made in surgery, chemotherapy, targeted therapy, and immunotherapy, many patients with advanced solid tumors still face limited treatment options, particularly after standard therapies fail. As a result, there is growing global demand for innovative therapies capable of improving survival and offering hope for patients with difficult-to-treat cancers.
Among the most promising breakthroughs is CAR-T cell therapy, a form of personalized cellular immunotherapy that is rapidly expanding beyond blood cancers into solid tumors such as stomach cancer and pancreatic cancer. China has become one of the leading countries driving this next generation of cancer treatment through advanced clinical research and innovative CAR-T development programs.
What Is a Solid Tumor?
A solid tumor is an abnormal mass of tissue formed by uncontrolled cell growth within an organ or body structure. Unlike blood cancers such as leukemia, solid tumors develop as localized masses that may eventually invade nearby tissues and spread to distant organs through metastasis.
Solid tumors can occur in many parts of the body, including the stomach, pancreas, lung, liver, colon and rectum, breast, brain, ovary, kidney, and prostate. These cancers represent some of the most common and challenging diseases treated in modern oncology.
Solid tumors are generally classified into several categories depending on the type of tissue from which they originate. The most common category is carcinoma, which develops from epithelial cells that line organs and tissues. Most major cancers, including stomach cancer and pancreatic cancer, are classified as carcinomas.
Another category is sarcoma, which originates from connective tissues such as muscle, bone, cartilage, or fat. Although less common than carcinomas, sarcomas can occur in both children and adults and often require specialized treatment approaches.
Solid tumors can also develop within the brain or spinal cord, known as central nervous system tumors. These tumors may affect neurological function depending on their location and size.
Symptoms of Solid Tumors
Symptoms depend on the location and stage of the cancer. Early-stage solid tumors may not cause noticeable symptoms, which is one reason many patients are diagnosed at advanced stages.
Common symptoms may include:
- Persistent pain
- Unexplained weight loss
- Fatigue
- Loss of appetite
- Digestive problems
- Difficulty swallowing
- Abdominal discomfort
- Persistent cough
- Bleeding
- Swelling or lumps
How Are Solid Tumors Diagnosed?
Accurate diagnosis is essential for selecting the most appropriate treatment strategy. Modern cancer diagnostics cAccurate diagnosis is important for determining the most appropriate treatment for solid tumors. Modern cancer diagnosis combines imaging studies, pathology, and molecular testing to identify the type and stage of cancer.
Imaging methods such as CT scans, MRI, PET-CT, ultrasound, X-ray, and endoscopy help physicians locate tumors and evaluate whether the cancer has spread. A biopsy is usually required to confirm the diagnosis, allowing tissue samples to be examined under a microscope.
Molecular and genetic testing are also increasingly important in cancer care. Biomarker testing for factors such as HER2, PD-L1, Claudin18.2 (CLDN18.2), KRAS mutations, microsatellite instability (MSI), and next-generation sequencing (NGS) can help guide targeted therapies and advanced immunotherapies including CAR-T cell therapy.
Current Treatment Options for Solid Tumors
Treatment for solid tumors depends on the type of cancer, its stage, molecular characteristics, and the patient’s overall condition. In many cases, a combination of therapies is used to achieve the best possible outcome.
Surgery remains one of the most important treatments for localized solid tumors and aims to remove the cancer completely whenever possible. Chemotherapy and radiation therapy are also widely used to shrink tumors, destroy cancer cells, and reduce the risk of recurrence.
In recent years, targeted therapy and immunotherapy have significantly changed cancer treatment by offering more precise approaches based on the biological features of the tumor. These therapies can help some patients achieve better disease control and improved survival.
However, many advanced solid tumors, particularly metastatic or treatment-resistant cancers, remain difficult to treat with conventional therapies alone. As a result, there is increasing global demand for innovative treatment options capable of providing longer-lasting responses and new hope for patients with limited alternatives.
One of the most promising emerging approaches is CAR-T cell therapy, an advanced form of cellular immunotherapy that is now being actively explored for solid tumors such as stomach cancer and pancreatic cancer in China.
Growing Demand for New Treatment Options
Although modern oncology has achieved major progress, many advanced solid tumors remain difficult to cure. Patients with metastatic or treatment-resistant cancers often experience limited long-term benefit from conventional therapies.
This challenge is especially serious in cancers such as stomach cancer and pancreatic cancer, where recurrence and progression rates remain high despite aggressive treatment.
As a result, there is increasing global demand for:
- More personalized cancer therapies
- Treatments with durable responses
- Innovative immunotherapies
- Better options for advanced-stage disease
- New therapies after chemotherapy failure
- Clinical trial access
This demand has accelerated research into cellular therapies, including CAR-T cell therapy for solid tumors.
What Is CAR-T Cell Therapy?
CAR-T cell therapy, or Chimeric Antigen Receptor T-cell therapy, is an advanced form of immunotherapy that modifies a patient’s own immune cells to recognize and destroy cancer cells. While CAR-T therapy has already transformed treatment for blood cancers such as leukemia and lymphoma, researchers are now rapidly expanding this technology into solid tumors.
China has become one of the global leaders in CAR-T research for solid tumors, with clinical studies targeting stomach cancer, pancreatic cancer, liver cancer, lung cancer, colorectal cancer, and other advanced malignancies. One of the most important breakthroughs has been the development of CAR-T therapies targeting Claudin18.2 (CLDN18.2), a protein commonly expressed in stomach cancer and some pancreatic cancers.
Early studies in China have shown encouraging results in patients with advanced solid tumors who previously failed standard treatments, including tumor shrinkage and disease stabilization. Researchers are also exploring additional targets such as HER2, Mesothelin, MUC1, GPC3, and PSCA while developing next-generation CAR-T technologies designed to improve effectiveness in solid tumors.
With strong biotechnology infrastructure, extensive clinical trial programs, and advanced cell therapy development, China is rapidly becoming an important center for innovative CAR-T treatment options for solid tumors.
The Future of Solid Tumor Treatment
The future of cancer treatment is increasingly focused on personalized and precision medicine. CAR-T cell therapy represents one of the most exciting developments for patients with advanced solid tumors who may have limited conventional options remaining.
For stomach cancer and pancreatic cancer, China is playing an important role in accelerating the development of next-generation CAR-T therapies that may reshape the future of solid tumor treatment worldwide.
As research continues to advance, cellular immunotherapy could become an important part of multidisciplinary cancer care for patients facing difficult-to-treat malignancies.
